Comparative Pharmacology
Head-to-head clinical analysis: NICODERM CQ versus NICORETTE MINT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICODERM CQ versus NICORETTE MINT.
NICODERM CQ vs NICORETTE (MINT)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicotine is a nicotinic cholinergic receptor agonist that stimulates ganglia and the CNS, leading to release of catecholamines and other neurotransmitters. In smoking cessation, it acts as a replacement therapy to reduce withdrawal symptoms and cravings by binding to nicotinic acetylcholine receptors in the brain.
Nicotine binds to nicotinic acetylcholine receptors (nAChRs) in the brain, stimulating dopamine release in the mesolimbic pathway, which reduces withdrawal symptoms and cravings associated with smoking cessation.
Apply one 7 mg/24 hour, 14 mg/24 hour, or 21 mg/24 hour transdermal patch to non-hairy, clean, dry skin on the upper body or upper outer arm once daily. Initial dose based on smoking status: patients smoking >10 cigarettes/day: 21 mg/24 hours; patients smoking ≤10 cigarettes/day: 14 mg/24 hours. Titrate based on withdrawal symptoms.
For smoking cessation, apply one 2 mg or 4 mg lozenge (mint) every 1-2 hours as needed for cravings, up to 15 lozenges per day. Use 4 mg lozenge if first cigarette is within 30 minutes of waking. Do not chew; allow to dissolve slowly (20-30 minutes). Frequency should be tapered after 6 weeks.
None Documented
None Documented
Terminal elimination half-life ~2 hours (range 1-4 h) after transdermal patch removal; clinically, levels decline rapidly, requiring scheduled reapplication.
2 hours (range 1-4) for nicotine; terminal half-life 10-12 hours for cotinine; clinical context: short t½ requires frequent dosing. Half-life prolonged in hepatic impairment.
Primarily renal; about 10-20% excreted unchanged, remainder as metabolites (cotinine and nicotine-N'-oxide). Total clearance ~1.2 L/min. Biliary/fecal excretion negligible (<5%).
Renal: 60-80% as metabolites (cotinine, nicotine N-oxide), 10-20% unchanged; biliary/fecal: <10%
Category C
Category C
Smoking cessation aid
Smoking cessation aid